176 related articles for article (PubMed ID: 26315514)
21. Implications of intratumour heterogeneity for treatment stratification.
Crockford A; Jamal-Hanjani M; Hicks J; Swanton C
J Pathol; 2014 Jan; 232(2):264-73. PubMed ID: 24115146
[TBL] [Abstract][Full Text] [Related]
22. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
[TBL] [Abstract][Full Text] [Related]
23. Fusion genes as biomarkers in pediatric cancers: A review of the current state and applicability in diagnostics and personalized therapy.
Vellichirammal NN; Chaturvedi NK; Joshi SS; Coulter DW; Guda C
Cancer Lett; 2021 Feb; 499():24-38. PubMed ID: 33248210
[TBL] [Abstract][Full Text] [Related]
24. Pediatric oncology enters an era of precision medicine.
Seibel NL; Janeway K; Allen CE; Chi SN; Cho YJ; Glade Bender JL; Kim A; Laetsch TW; Irwin MS; Takebe N; Tricoli JV; Parsons DW
Curr Probl Cancer; 2017; 41(3):194-200. PubMed ID: 28343740
[TBL] [Abstract][Full Text] [Related]
25. Biomarkers of Bad Biology: Curse or a Blessing?
Banerjee S; Sicklick JK
Ann Surg Oncol; 2019 Feb; 26(2):318-320. PubMed ID: 30539488
[No Abstract] [Full Text] [Related]
26. Speeding towards individualized treatment for pancreatic cancer by taking an alternative road.
Iovanna J; Dusetti N
Cancer Lett; 2017 Dec; 410():63-67. PubMed ID: 28947138
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy.
Lee JK; Liu Z; Sa JK; Shin S; Wang J; Bordyuh M; Cho HJ; Elliott O; Chu T; Choi SW; Rosenbloom DIS; Lee IH; Shin YJ; Kang HJ; Kim D; Kim SY; Sim MH; Kim J; Lee T; Seo YJ; Shin H; Lee M; Kim SH; Kwon YJ; Oh JW; Song M; Kim M; Kong DS; Choi JW; Seol HJ; Lee JI; Kim ST; Park JO; Kim KM; Song SY; Lee JW; Kim HC; Lee JE; Choi MG; Seo SW; Shim YM; Zo JI; Jeong BC; Yoon Y; Ryu GH; Kim NKD; Bae JS; Park WY; Lee J; Verhaak RGW; Iavarone A; Lee J; Rabadan R; Nam DH
Nat Genet; 2018 Oct; 50(10):1399-1411. PubMed ID: 30262818
[TBL] [Abstract][Full Text] [Related]
28. Precision and predictive medicine in urothelial cancer: are we making progress?
Bellmunt J; Orsola A; Sonpavde G
Eur Urol; 2015 Oct; 68(4):547-9. PubMed ID: 25935702
[TBL] [Abstract][Full Text] [Related]
29. Precision medicine: In need of guidance and surveillance.
Lin JZ; Long JY; Wang AQ; Zheng Y; Zhao HT
World J Gastroenterol; 2017 Jul; 23(28):5045-5050. PubMed ID: 28811702
[TBL] [Abstract][Full Text] [Related]
30. Somatic Mutation Analysis of Human Cancers: Challenges in Clinical Practice.
Tsongalis GJ; Coleman WB
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S60-S66. PubMed ID: 28921651
[TBL] [Abstract][Full Text] [Related]
31. New therapeutic options opened by the molecular classification of gastric cancer.
Chivu-Economescu M; Matei L; Necula LG; Dragu DL; Bleotu C; Diaconu CC
World J Gastroenterol; 2018 May; 24(18):1942-1961. PubMed ID: 29760539
[TBL] [Abstract][Full Text] [Related]
32. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
Molloy MP; Engel A
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786
[No Abstract] [Full Text] [Related]
33. Precision Medicine.
Khatri VP; Petrelli NJ
Surg Oncol Clin N Am; 2020 Jan; 29(1):xv-xvi. PubMed ID: 31757318
[No Abstract] [Full Text] [Related]
34. What have we learned from exceptional tumour responses?: Review and perspectives.
Mehra N; Lorente D; de Bono JS
Curr Opin Oncol; 2015 May; 27(3):267-75. PubMed ID: 25811347
[TBL] [Abstract][Full Text] [Related]
35. Targeting dynamics of subclones of GI, liver and pancreatic cancers.
Ziogas DE; Glantzounis G; Liakakos T; Roukos DH
Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):773-6. PubMed ID: 27143511
[No Abstract] [Full Text] [Related]
36. Impact of the biomarker enrichment strategy in drug development.
Lara Gongora AB; Carvalho Oliveira LJ; Jardim DL
Expert Rev Mol Diagn; 2020 Jun; 20(6):611-618. PubMed ID: 31903795
[TBL] [Abstract][Full Text] [Related]
37. [Precision medicine from experimental to clinical applications in oncology].
Normanno N
Recenti Prog Med; 2015 Dec; 106(12):597-600. PubMed ID: 26780068
[TBL] [Abstract][Full Text] [Related]
38. Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference.
Tan DS; Gerlinger M; Teh BT; Swanton C
Eur J Cancer; 2010 Aug; 46(12):2166-77. PubMed ID: 20413300
[TBL] [Abstract][Full Text] [Related]
39. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
40. Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics.
Wijdeven RH; Pang B; Assaraf YG; Neefjes J
Drug Resist Updat; 2016 Sep; 28():65-81. PubMed ID: 27620955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
